ORIGINAL RESEARCH article
Front. Oncol., 10 September 2020
Sec. Pharmacology of Anti-Cancer Drugs
Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.01756
RETRACTED: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway
- XL
Xiaozhong Liao 1,2,3†
- YG
Ying Gao 1†
- JL
Jiahui Liu 1,3†
- LT
Lanting Tao 1
- DW
Dongmei Wang 4
- DX
Dan Xie 2*
- SM
Suilin Mo 1*
1. Department of Traditional Chinese Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2. The State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
3. Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
4. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
Summary
Citation
Liao X, Gao Y, Liu J, Tao L, Wang D, Xie D and Mo S (2020) RETRACTED: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway. Front. Oncol. 10:1756. doi: 10.3389/fonc.2020.01756
Received
06 February 2020
Accepted
05 August 2020
Published
10 September 2020
Volume
10 - 2020
Edited by
Francisco Estévez, University of Las Palmas de Gran Canaria, Spain
Reviewed by
Diwakar Bastihalli Tukaramrao, University of Toledo, United States; Zui Pan, University of Texas at Arlington, United States
Updates
†These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.